The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.

The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.

The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

An application of an antibody conjugate in the preparation of a drug for treating CD30 positive tumors, which is characterized in that: the antibody conjugate is F0002-ADC; the general formula of the structural thereof is Ab-L.sub.m-Y.sub.n; and the CD30-positive tumors are CD30-positive tumors that express a multidrug resistance gene 1. In addition, a pharmaceutical combination and a pharmaceutical composition containing the antibody conjugate, which may be applied to the preparation of a drug used for treating CD30-positive tumors.

An application of an antibody conjugate in the preparation of a drug for treating CD30 positive tumors, which is characterized in that: the antibody conjugate is F0002-ADC; the general formula of the structural thereof is Ab-L.sub.m-Y.sub.n; and the CD30-positive tumors are CD30-positive tumors that express a multidrug resistance gene 1. In addition, a pharmaceutical combination and a pharmaceutical composition containing the antibody conjugate, which may be applied to the preparation of a drug used for treating CD30-positive tumors.

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.

The present invention relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.